Most processes for fabricating biosensors applied to screen-printed carbon electrodes (SPCEs) are complex. This study presents a novel one-step process for manufacturing electrodes for injection-molding biosensors.
are indispensable home-use devices for effective control of glycemia levels by diabetes patients (1 ) . Monitoring blood glucose concentrations requires a reliable and affordable measurement system, and many improvements have been made in the last few decades to enhance SMBG meter performance (2) (3) (4) (5) (6) (7) (8) . These enhancements include an improved methodology, use of a redox mediator, and simplified processes for manufacturing electrodes. For instance, glucose dehydrogenases, such as quinoprotein glucose dehydrogenase, and flavoprotein glucose dehydrogenase, were introduced to improve the accuracy of glucose measurement and make it O 2 -insensitive. Various screen-printed carbon electrodes (SPCEs) have been developed, and these electrodes have the advantages of simplicity, low cost, and the potential for mass production (9, 10 ) . Major problems can still occur with SPCE techniques, however, as when polymers in the ink increase electrontransfer resistance, for example. In addition, inconsistency of the electrochemical area of SPCEs may produce imprecise measurements of blood glucose concentrations (4, 11 ) .
Pretreating SPCEs can enhance the electrochemical properties of carbon electrodes, including electrochemical response, response time, cyclical voltammetric behavior, and mechanical stability (4, 12 ) . Therefore, such processes as electroplating of copper (13 ) and sputtering of palladium and gold (11, 14 ) have frequently been used to modify electrodes and thereby accelerate electron-transfer kinetics and reduce the potential required. Fabrication processes applied to most SPCE-based devices are extremely complex, however, and thus a simple process is required. This study investigated a novel technique for fabricating amperometric glucose biosensors that involved inserting barrel-plated gold electrodes into hollow holes in the injection-molded base, followed by immobilization of chemical reagents on a U-shaped furrow. This technique has the potential for producing manufacturing costs as low as those for the SPCE technique. Furthermore, gold particles generate large and specific areas that can immobilize most glucose oxidase molecules on the biosensing interface, and the excellent conductivity of gold accelerates electron transfer (14 -16 ) . This novel electrode-manufacturing technique for amperometric biosensors has been patented in the US (17 ) .
Although commercially available glucose meters have been developed for alternative-site testing, the stability of measurements has been an ongoing topic of study in arm tests (18, 19 ) . The aim of this study was to characterize and evaluate the clinical performance of the Bionime Rightest GM310 meter for alternative-site tests (e.g., fingertips, palms, and arms) with novel test strips fabricated by means of a one-step electrodemanufacturing process.
Materials and Methods

STUDY PARTICIPANTS
We enrolled 139 diabetic and nondiabetic patients in clinical trials at the outpatient clinic of Min-Sheng General Hospital (accredited by Joint Commission International), Taoyuan City, Taiwan. The clinical trial evaluated the performance of Bionime Rightest SMBG system GM310. The age range of the 139 volunteers (49 men and 90 women) was 21-84 years. The study participants were not necessarily users of Bionime Rightest meters. Informed consent was obtained from each participant, and the study protocol was reviewed and approved by the clinical trial committee of Min-Sheng General Hospital for experiments involving humans (MSEIRB Authority no. 951206).
BLOOD GLUCOSE METERS
This study used Rightest SMBG system GM310 (Bionime) and a new test strip. The meter used amperometric electrochemistry to measure capillary blood glucose concentrations. The meter required a 0.6-L blood sample and reported a venous plasma-equivalent glucose concentration in 5 s. The test strip was 40 mm long and 9 mm wide. The test strip consisted of an injection-molded base, enzyme-modified goldplated electrodes, chemical reagent, and a cover film (Fig. 1) . The test strips were from the same batch (lot no. 1178062).
TEST PROCEDURES
The analytical measurement range was evaluated by assaying venous blood samples spiked with various glucose concentrations (range, 0.6 -33. Supplementary Fig. 1 (see the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol54/issue10) describes the clinical trial procedures. Trained technicians and nurses performed measurements according to the user manual with the meter at room temperature. Manufacturer-recommended methods were used to obtain blood samples from the fingertip, palm, and arm. We used the hexokinase method on an Olympus AU640 instrument (Olympus America) as a comparison method. The clinical trial was funded by Bionime Technology, Taiwan. 
Results
IMPRECISION TEST AND LINEARITY ANALYSIS
The Rightest GM310 method showed excellent linearity over the analytical measurement range of blood glucose concentrations (0.6 -33.3 mmol/L), with the following meter results: y ϭ 0.96x ϩ 0.07 mmol/L; r 2 ϭ 0.9977 (Fig. 2) .
The imprecision results are shown in Table 1 . Within-run CVs were 1.7%-3.5%, and the overall CV was 2.1%, excluding the SD value of 0.08 mmol/L for extra-low glucose concentrations (Table 1) . For between-meter tests, differences in mean values were not statistically significant (P Ͼ 0.05, paired t-test). The maximum mean difference among the 5 meters was 0.08 mmol/L or a 1.6% variation (Table 1) .
CLINICAL EVALUATION OF RIGHTEST BLOOD
GLUCOSE-MONITORING SYSTEM GM310
The capillary blood glucose concentration was measured at the fingertip, the palm, and the arm. Within 5 min after values were obtained with the Rightest GM310, we drew a venous sample from the same individual, centrifuged the sample for 10 min, and analyzed it within 1 h at the Min-Sheng General Hospital with an Olympus AU640 chemistry analyzer. Supplementary Fig. 1 in the online Data Supplement shows the flow chart of this clinical trial. The range of blood glucose concentrations for the 139 study participants was 1.6 -26.7 mmol/L, and hematocrits met the manufacturer's criteria (30%-55%). The agreement between the Rightest GM310 results and the comparison-method results (Olympus AU640) was clinically satisfactory (Table 2 ; Fig. 3 ).
In addition to fingertip tests, this study measured values from palm and arm sites. Although 139 measurements from the participants' arms produced 5 results that failed to fall within the Ϯ20% interval of reference values, the agreement of the values for the Rightest GM310 and the comparison method was clinically acceptable.
An EGA results for the fingertip test (Fig. 4A) were within acceptable zone A in 97.8% of the cases. In the palm and arm tests, 100% of the values were within zones A plus B (97.8% and 96.4%, respectively, within zone A; 2.2% and 3.6% within zone B; Fig. 4, B and C) . The EGA results demonstrate that Rightest SMBG meter GM310 was clinically acceptable for use with alternative test sites.
Discussion
In this study, within-run imprecision tests demonstrated that the mean CV of the Bionime Rightest GM310 meter was 2.1%. Commercially available meters that apply the SPCE technique have CVs in the range of 3%-6% (21-23 ) . The imprecision of glucose meter measurements has been attributed to inconsistency in the electrochemical response area (11 ) . In the present study, efficient control of the electrochemical area seemed to effectively improve the imprecision. Additionally, gold electrodeposition during electrode manufacturing has better precision than the sputtering process because of the former's electrochemical reproducibility (11 ) . We suggest that the superior precision of the GM310 may be attributed to its simplified fabrication technique (24 ) .
The EGA results showed that 100% of the values fell within clinically acceptable zones A and B, suggesting that results obtained in alternative-site tests with the Rightest GM310 meter are clinically acceptable. According to ISO 15197:2003 criteria, the Bionime Rightest GM310 has met the requirements of SMBG systems for testing at alternative sites (fingertip, palm, and arm).
More than 50% of the values generated with the Bionime Rightest GM310 meet the alternative-site test criteria of the American Diabetes Association, which recommends that 100% of the values fall within the Ϯ5% interval of comparison-method values (25, 26 ) . Currently, only 15%-50% of values of most commercially available glucose meters meet this criterion (7, 22, 23, 26 -28 ) , and the performance of the Rightest meter is consistent with that of other meters. Several complicating methodologic factors should be considered when a comparison method is used. The glucose concentration of capillary whole blood is lower than that of venous plasma (29 ) . This difference is partly attributable to the hematocrit, or a fasting vs nonfasting state. One potential limitation of the performance of the Rightest GM310 is the hematocrit in a blood sample. Many studies have concluded that variation in the hematocrit significantly reduces the accuracy of SMBG measurements. A high hematocrit is associated with underestimation, whereas a low hematocrit causes overestimation of glucose concentrations (30 -32 ) . Therefore, hematocrits may constitute a significant clinical risk in evaluating the hypoglycemia symptoms that are encountered in the up to 20% of the neonatal population that commonly has high hematocrits (33, 34 ) . We analyzed the effect of hematocrits in this clinical trial and obtained results similar to those of prior hematocrit studies. Fig. 2 in the online Data Supplement shows the effect of the hematocrit on glucose measurement.
In summary, the Bionime Rightest GM310 complies with ISO 15197:2003 criteria and produces acceptable glucose results for alternative test sites (fingertip, palm, or arm) that are generally equivalent. 
